Apheresis enhances the selective removal of antinuclear antibodies in systemic lupus erythematosus.
Apheresis suppresses clinical manifestations of lupus and reduces levels of antinuclear antibodies implicated in the pathogenesis of systemic lupus erythematosus (SLE). It is not known, however, if reduced levels of antinuclear antibodies are due to nonspecific removal, or specific mechanisms associated with decreased production, or enhanced clearance from the circulation. In order to distinguish between specific and nonspecific effects of apheresis on antinuclear antibodies in SLE, we compared plasma levels of IgG antibodies to DNA and IgG antibodies to microbial antigens in 13 SLE patients before and after apheresis. Although apheresis lowered plasma levels of IgG (21% mean reduction), there was a disproportionate reduction in IgG antibodies to DNA (42% mean reduction, p less than 0.13). In marked contrast, reduction in antibodies to microbial antigens did not exceed those of plasma IgG. A rapid rebound of serum anti-DNA antibodies following apheresis in certain SLE patients suggests that the selective reduction in anti-DNA antibodies is due to enhanced clearance from the circulation rather than decreased production. These results indicate that apheresis enhances selective removal of antinuclear antibodies in some patients with SLE.
Colburn
K K
KK
Department of Medicine, Loma Linda University, California.
Gusewitch
G A
GA
Statian Pooprasert
B S
BS
Weisbart
R H
RH
D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis*; D000942:Antigens, Bacterial / Q000032:analysis; D000956:Antigens, Viral / Q000032:analysis; D001781:Blood Component Removal; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000276:immunology / Q000628:therapy*; D008297:Male
D000974:Antibodies, Antinuclear; D000942:Antigens, Bacterial; D000956:Antigens, Viral; D007074:Immunoglobulin G